Skip to main content
Kenneth Kehl, MD, Oncology, Boston, MA

KennethLKehlMD

Oncology Boston, MA

Instructor in Medicine-Hospital Medicine, Northwestern University Medical School

Dr. Kehl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kehl's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Boston, MA 02215
    Phone+1 617-632-3468

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 2008

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2012 - 2026
  • NH State Medical License
    NH State Medical License 2024 - 2024
  • TX State Medical License
    TX State Medical License 2014 - 2019
  • IL State Medical License
    IL State Medical License 2010 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Lectures

  • Clinical trajectory modeling to predict hospitalization or death after palliative chemotherapy. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Computer Platform Helps Match Patients with Cancer to Trials of Targeted Therapy
    Computer Platform Helps Match Patients with Cancer to Trials of Targeted TherapyOctober 12th, 2022
  • Lack of Guideline-Concordant Treatment for Early-Stage Non-Small Cell Lung Cancer Common
    Lack of Guideline-Concordant Treatment for Early-Stage Non-Small Cell Lung Cancer CommonMay 13th, 2022
  • ‘More Effort Needed’ to Optimize Use of Standard Early NSCLC Therapies
    ‘More Effort Needed’ to Optimize Use of Standard Early NSCLC TherapiesMarch 22nd, 2022
  • Join now to see all

Professional Memberships